Walk Ahead for a Brain Tumor Cure on Oct. 21
Thousands expected at annual event
Event Information (passed)
The ninth annual Walk Ahead for a Brain Tumor Cure is Sunday, Oct. 21, 2018 at Sawyer Point.
- Registration begins at 7:30 a.m.
- Timed 5K run begins at 8:30 a.m.
- 5K walk begins at 9 a.m.
- Wheelchair friendly 2K begins at 9 a.m.
Thousands of walkers and runners will support research and educational efforts of the University of Cincinnati Brain Tumor Center at the University of Cincinnati Gardner Neuroscience Institute.
Now nearly a decade in existence, Walk Ahead 2018 will have raised $2 million over its entire lifetime, following the 2018 event.
Brain tumors are not uncommon. More than 200,000 people are stricken with brain tumors in America every year. During the last two decades, the frequency of brain tumors has increased 22 percent overall and 55 percent in people over 65 years of age. The University of Cincinnati Brain Tumor Center is a regional destination for brain tumor patients, providing compassionate care while striving to find causes and cures. The funds raised through Walk Ahead advance the innovative research necessary to developing new treatments.
Related Stories
Chris Higgins named UC Foundation Vice President for Development, Academic Health Enterprise
January 6, 2026
The University of Cincinnati Foundation is pleased to welcome Chris Higgins as the new Vice President for Development, Academic Health Enterprise.
What's behind the mysterious rise of migraines?
January 5, 2026
Weather patterns such as extreme heat and storm conditions have been linked to migraine attacks, and research shows those environmental conditions are becoming more common. As National Geographic recently reported, one of the leading theories behind this mysterious rise is that climate change may be playing a role.
Top six 2025 nephrology drug approvals
January 5, 2026
“2025 has been a landmark year for kidney disease therapeutics, marked by a comprehensive slate of FDA approvals covering endothelin-receptor blockade, complement inhibition, GLP-1-based metabolic protection, and B-cell-directed therapy,” Prakash Gudsoorkar, MD, associate professor of clinical medicine at the University of Cincinnati College of Medicine and staff nephrologist at UC Health, recently told MedCentral.